Skip to main content

Table 3 Distribution of CYP2C19*2, *3 and PON1 genotypes in clopidogrel responder and non-responder group

From: The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention

 GenotypeNon-responders
(40)
responders
(120)
P
CYP2C19a1/a1(681GG/636GG)4(10%)61(50.83%)< 0.001
(a2:681G > Aa1/a2(681GA/636GG)13(32.5%)45(37.5%)0.569
a3:636G > A)a1/a3(681GG/681GA)5(8%)7(5.83%)0.177
 a2/a2(681AA/636GG)11(27.5%)6(5%)< 0.001
 a2/a3(681GA/636GA)7(17.5%)1(0.83%)< 0.001
a3/a3(681GG/636AA)00 
PONQ192RAA(QQ)2(5%)21(17.5%)0.172
(575A > G)    
 AG(QR)11(27.5%)53(44.17%)0.066
GG(RR)27(67.5%)46(38.33%)0.001
  1. a Variable is significant difference between responders and non-responders at p-value< 0.05